QUANTUM BIOPHAR (QNTM)
(Delayed Data from NSDQ)
$24.57 USD
-3.23 (-11.62%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $24.20 -0.37 (-1.51%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
QNTM 24.57 -3.23(-11.62%)
Will QNTM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for QNTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QNTM
QUANTUM BIOPHAR (QNTM) Upgraded to Buy: Here's What You Should Know
QNTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNTM
Quantum BioPharma (QNTM) Advances Lucid-MS Development Following Positive Trial
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 ...
Quantum Group subsidiary received CSR for Phase 1 MAD trial
Quantum BioPharma (QNTM) Counters Motion to Dismiss in Market Manipulation Case
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, ...